About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

AstraZeneca Initiates Phase III Program for Selumetinib

by Kathy Jones on October 24, 2013 at 9:06 PM
Font : A-A+

 AstraZeneca Initiates Phase III Program for Selumetinib

London-based pharmaceutical company AstraZeneca revealed that it began late stage trials for its investigative MEK inhibitor selumetinib to test its effectiveness as a potential treatment for non-small-cell lung cancer.

The company will enroll 634 NSCLC patients in the SELECT-1 (SELumetinib Evaluation as Combination Therapy-1) study. The study aims to compare the safety and efficacy of selumetinib in combination with Taxotere (Sanofi's version of docetaxel) to Taxotere and placebo. Progression free survival (PFS) and overall survival will be the main parameters in the study.

Advertisement

AZ has taken this step following encouraging results from phase II trials, where selumetinib plus Taxotere resulted in progression free survival of 5.3 months versus 2.1 months in the Taxotere alone arm.


Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
First Dose of COVID-19 Vaccines May Improve Mental Health
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Top Ten Selling Drugs 

Recommended Reading
Lung Cancer Screening
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can ......
Lung Biopsy
The procedure by which tissue samples are obtained from the lung is known as lung biopsy. The ......

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use